Publicações Científicas da Odontologia Brasileira Relacionadas ao COVID-19

Titulo: Recommendations for a safety dental care management during SARS-CoV-2 pandemic


Autor

Paulo Ricardo Martins-Filho, Vanessa Tavares de Gois-Santos, Carolina Santos Souza Tavares, Elisama Gomes Magalhães de Melo, Edmundo Marques do Nascimento-Júnior e Victor Santana Santos.

Resumo

Como o SARS-CoV-2, que causa síndrome respiratória aguda grave, é transmitido principalmente por gotículas, espirros e aerossóis, há um alto risco de transmissão durante os procedimentos odontológicos. Este relatório descreve os passos que podem ser tomados pelo pessoal de saúde oral para minimizar o risco de contaminação cruzada na prática clínica durante a actual pandemia do SARS-CoV-2.

Publicado em "Pan American Journal of Public Health" (2020)

Titulo: No evidence supports the use of ether and chloroform inhalation for treating COVID-19


Autor

Paulo Ricardo Martins-Filho e Victor Santana Santos.

Resumo

Dear Editor, SARS-CoV-2 has been spreading rapidly across the world as well as the number of fake news on social media regarding harmful or non-harmful treatments which are ineffective for treating COVID-19. In Brazil, the first case of COVID-19 was confirmed on February 26, 2020 and until March 20, 2020 at least 970 cases and seven deaths have been reported. The fear and uncertainty have led people to consume and share mistrust and misinformation on the Internet. Since the first confirmed case in Brazil, fake news about the effectiveness of an ether and chloroform blend known as “lança perfume” or “loló” were spread on social media. Nowadays, the ecosystem of big data has provided valuable information about online health-related behaviour and new patterns among population groups using social media data.

Publicado em "Pan American Journal of Public Health" (2020)

Titulo: Cuidados Odontológicos na era do COVID-19:recomendações para procedimentos odontológicos e profissionais


Autor

Juliana Bertoldi Franco, Alessandra Rodrigues de Camargo e Maria Paula Siqueira de Melo Peres

Resumo

A pandemia pelo SARS-CoV-2 faz com que muitos profissionais de saúde modifiquem seus atendimentos, entre eles o Cirurgião-Dentista. Este momento proporcionou mudanças na Odontologia, ocasionando uma alteração expressiva na forma de atendimento e da rotina dos consultórios odontológicos.

Publicado em "REV ASSOC PAUL CIR DENT " (mar/2020)

Titulo: Extensive hard palate hyperpigmentation associated withchloroquine use


Autor

Géssica Vasconcelos Godinho, Ana Luiza Lima Medeiros Paz, Elâine Patrícia Alves de Araújo Gomes, Cristiane Loreda Garcia e Luiz Evaristo Ricci Volpato

Resumo

LETTER TO THE EDITORExtensive hard palate hyperpigmentation associated withchloroquine useA 66-year-old woman diagnosed clinical manifestation ofextensive hard palate hyperpigmentation is presented. Dueto historic of rheumatoid arthritis and use of chloroquinephosphate for 3 years, exogenous hyperpigmentation asso-ciated with the drug was included among the possible diag-noses. Incisional biopsy was performed and thehistopathological exam confirmed exogenous hyper-pigmentation compatible with chloroquine use. The patientwas referred to the rheumatologist and the ophthalmolo-gist for evaluation of the continuity of the chloroquine use.After one year of follow-up, no changes were seen in thehyperpigmentation nor other clinical changes. Hyperpigmentation of the hard palate by the use of chloroquine is one of the adverse effects of the chronic use of this drug and does not require specific treatment. The adequate anamnesis and the knowledge about the adverse effects of the drug allowed an adequate therapeutic approach in the case.

Publicado em "British Pharmacological Society | Journals" (27 March 2020)

Titulo: Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection


Autor

Paulo Martins-Filho, Aline Carla Carvalho, Elisama Magalhães de Melo, Mário Luis Tavares Mendes e Victor Santos.

Resumo

The use of either chloroquine or hydroxychloroquine and azithromycin for treatment or prevention of SARS-CoV-2 infection is currently supported primarily by in vitro data and weak studies involving humans. Physicians and patients should be aware of several uncommon but potentially life-threatening adverse effects should these drugs be used before better-designed studies determine their benefit, if any, in treating or preventing COVID-19. Harms of treatment can be mitigated by careful patient selection and monitoring.

Publicado em "CMAJ" (27 de abril de 2020 192)

Titulo: Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing


Autor

Luca Ferretti, Chris Wymant, Michelle Kendall, Lele Zhao, Anel Nurtay, Lucie Abeler-Dörner, Michael Parker, David Bonsall e Christophe Fraser

Resumo

Coronavirus disease 2019(COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has clear potential for a long-lasting global pandemic, high fatality rates, and incapacitated health systems. Until vaccines are widely available, the only available infection prevention approaches are case isolation, contact tracing and quarantine, physical distancing, decontamination, and hygiene measures. To implement the right measures at the right time, it is of crucial importance to understand the routes and timings of transmission.

Publicado em "RESEARCH" (08 de maio de 2020)

Titulo: The effect of human mobility and control measures on the COVID-19 epidemic in China


Autor

Moritz U. G. Kraemer, Chia-Hung Yang, Bernardo Gutierrez, Chieh-Hsi Wu, Brennan Klein, David M. Pigott, Louis du Plessis, Nuno R. Faria, Ruoran Li, William P. Hanage, John S. Brownstein, Maylis Layan, Alessandro Vespignani, Huaiyu Tian, Christopher Dye, Oliver G. Pybus e Samuel V. Scarpino

Resumo

The outbreak of coronavirus disease 2019(COVID-19) spread rapidly from its origin in Wuhan, Hubei Province, China (1). A range of interventions were implemented after the detection in late December 2019 of a cluster of pneumonia cases of unknown etiology and identification of the causative virus, severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), in early January 2020 (2). Interventions include improved rates of diagnostic testing; clinical management; rapid isolation of suspected cases, confirmed cases, and contacts; and, most notably, restrictions on mobility (hereafter called cordon sanitaire) imposed on Wuhan city on 23 January 2020. Travel restrictions were subsequently imposed on 14 other cities across Hubei Province, and partial movement restrictions were enacted in many cities across China. Initial analysis suggests that the Wuhan cordon sanitaire resulted in an average 3-day delay of COVID-19 spread.

Publicado em "RESEARCH" (D01 May 2020)

NOTA


Para encaminhar sua produção científica para publicação na presente página, basta salvar o arquivo em formato PDF e enviar para producaocientifica@cfo.org.br. É importante ressaltar que o conteúdo enviado será analisado pela Diretoria do CFO, considerando o reconhecimento da comunidade científica.